Legal status by country
Is BPTES legal?
Written by Aaron CuhaReviewed Sep 2026
How BPTES is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Not approved; research use only | Not licensed | Not approved | Not approved |
| Note | None recorded | None recorded | None recorded | None recorded |
US FDA status: Not approved and not in clinical development. A preclinical research compound with no registered human trial. The orally bioavailable glutaminase inhibitor in this class, telaglenastat, reached randomised oncology trials and is also unapproved.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.